After weeks of donating the antiviral drug remdesivir to hospitals with severely ill coronavirus patients, the drug’s maker, Gilead Sciences, announced that it has settled on a price: $390 per vial, which works out to be roughly $2,340 per treatment course https://nyti.ms/38cdKjT ">https://nyti.ms/38cdKjT&q...
Until recently remdesivir was the only drug shown to help severely ill Covid-19 patients. But the benefits were modest, and the drug did not improve survival in those patients. Read more here. https://nyti.ms/38cdKjT ">https://nyti.ms/38cdKjT&q...
Gilead Sciences will distribute remdesivir under an unusual agreement with the U.S. government that establishes nonnegotiable prices and prioritizes American patients, health officials announced https://nyti.ms/38bX4ZT ">https://nyti.ms/38bX4ZT&q...
House Democrats passed a bill to cap Americans& #39; health insurance costs and give the government power to negotiate drug costs hours after the Trump administration announced it had secured remdesivir courses. Gilead Sciences is charging $2,340 per course. https://nyti.ms/2BMyYsy ">https://nyti.ms/2BMyYsy&q...